Matinas BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference
September 19 2017 - 8:20AM
Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage
biopharmaceutical company focused on developing innovative
anti-infectives for orphan indications, announced today that Jerome
D. Jabbour, Co-Founder and President, will present at the Cantor
Fitzgerald Global Healthcare Conference on Tuesday, September 26,
2017 at 4:35 PM EDT in New York, NY.
As part of his presentation, Mr. Jabbour will
provide a clinical update of the Company’s Phase 2 program of its
lead antifungal product candidate, MAT2203, an orally administered,
encochleated formulation of amphotericin B (a broad spectrum
fungicidal agent). Mr. Jabbour will discuss the Company’s clinical
and regulatory strategy for this program, including its plans to
engage with the U.S. Food and Drug Administration (“FDA”) to review
the compelling overall human safety, tolerability and efficacy data
package generated with MAT2203 to date with the goal of entering
Phase 3 for the prevention of invasive fungal infections as quickly
as possible.
Additionally, Mr. Jabbour will discuss the
Company’s clinical program for product candidate, MAT2501, an
orally administered, encochleated formulation of the broad spectrum
aminoglycoside antibiotic, amikacin, to treat gram-negative
bacterial infections and other intercellular bacterial infections.
In March 2017, Matinas reported positive topline data from the
Phase 1 single-ascending dose study of MAT2501 in healthy
volunteers and has plans to commence a Phase 1 multiple ascending
dose PK/tolerability study of MAT2501 in healthy volunteers in the
fourth quarter of 2017.
In addition to the presentation, management will
also be available to participate in one-on-one meetings with
qualified members of the investor community who are registered to
attend the conference.
A live audio webcast of the presentation will be
available on the Events page of the Investors section of the
Company’s website (www.matinasbiopharma.com). A webcast replay will
be accessible for 90 days following the live presentation.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage
biopharmaceutical company focused on developing innovative
anti-infectives for orphan indications. The Company's proprietary,
disruptive technology utilizes lipid-crystal nano-particle
cochleates to nano-encapsulate existing drugs, making them safer,
more tolerable, less toxic and orally bioavailable.
The Company's lead anti-infective product
candidates, MAT2203 and MAT2501, position Matinas BioPharma to
become a leader in the safe and effective delivery of
anti-infective therapies utilizing its proprietary lipid-crystal
nano-particle cochleate formulation technology. For more
information, please visit www.matinasbiopharma.com and connect with
the Company on Twitter, LinkedIn, Facebook, and Google+.
Forward Looking Statements:
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including those relating to the Company's strategic focus and the
future development of its product candidates, including MAT2203 and
MAT2501, the anticipated timing of regulatory submissions, the
anticipated timing of clinical studies, the Company’s ability to
identify and pursue development and partnership opportunities for
its products or platform delivery technology on favorable terms, if
at all, and the ability to obtain required regulatory approval and
other statements that are predictive in nature, that depend upon or
refer to future events or conditions. All statements other than
statements of historical fact are statements that could be
forward-looking statements. Forward-looking statements include
words such as "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to obtain additional capital to meet our liquidity needs on
acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials of our product
candidates; our ability to successfully complete research and
further development and commercialization of our product
candidates; the uncertainties inherent in clinical testing; the
timing, cost and uncertainty of obtaining regulatory approvals; our
ability to maintain and derive benefit from the Qualified
Infectious Disease Product (QIDP), Orphan and/or Fast Track
designations for MAT2203 and MAT2501, which does not change the
standards for regulatory approval or guarantee regulatory approval
on an expedited basis, or at all; our ability to protect the
Company's intellectual property; the loss of any executive officers
or key personnel or consultants; competition; changes in the
regulatory landscape or the imposition of regulations that affect
the Company's products; and the other factors listed under "Risk
Factors" in our filings with the SEC, including Forms 10-K, 10-Q
and 8-K. Investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this release. Except as may be required by law, the Company does
not undertake any obligation to release publicly any revisions to
such forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events. Matinas BioPharma's product candidates are all in a
development stage and are not available for sale or use.
Investor ContactJenene ThomasJenene Thomas
Communications, LLCPhone: +1 (908) 938-1475Email:
jenene@jenenethomascommunications.com